APA (7th ed.) Citation

Siegel, D. S., & Goldschmidt, H. (2016). VANTAGE 095: An international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory multiple myeloma. Clinical lymphoma, myeloma & leukemia, 16(6), . https://doi.org/10.1016/j.clml.2016.02.042

Chicago Style (17th ed.) Citation

Siegel, David S., and Hartmut Goldschmidt. "VANTAGE 095: An International, Multicenter, Open-label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia 16, no. 6 (2016). https://doi.org/10.1016/j.clml.2016.02.042.

MLA (9th ed.) Citation

Siegel, David S., and Hartmut Goldschmidt. "VANTAGE 095: An International, Multicenter, Open-label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia, vol. 16, no. 6, 2016, https://doi.org/10.1016/j.clml.2016.02.042.